In liver transplant recipients on an mTOR-inhibitor–based regimen who develop refractory hypertriglyceridemia, what triglyceride level and pancreatitis-risk features prompt you to change immunosuppression (dose reduction or switching off mTOR inhibition) rather than escalating lipid- lowering therapy alone?